Anamorelin shown to improve appetite and body mass in patients with cancer anorexia-cachexia
9/29/2014
A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014...
According to a recent study in the journal Human Vaccines & Immunotherapeutics (HV&I), only 60% of young US women who received the first dose of the human papilloma virus (HPV) vaccine went on to...
A recently published study comparing three FDA-approved screening tests for human papillomavirus (HPV) provides the latest confirmation of superior sensitivity for QIAGEN's digene HC2 HPV DNA Test.
Customising chemotherapy in lung cancer
9/29/2014
Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown at the ESMO 2014 Congress in...
Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous lung cancer
9/29/2014
The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free...
French studies measure benefits of colorectal cancer screening
9/29/2014
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have...
According to a recent study in the journal Human Vaccines & Immunotherapeutics (HV&I), only 60% of young US women who received the first dose of the human papilloma virus (HPV) vaccine went on to...
A recently published study comparing three FDA-approved screening tests for human papillomavirus (HPV) provides the latest confirmation of superior sensitivity for QIAGEN's digene HC2 HPV DNA Test.
Strategy to reduce side effects in modern cancer therapy
9/29/2014
An interdisciplinary team of researchers from the University of Vienna (Institute of Inorganic Chemistry) and the Medical University of Vienna (Institute for Cancer Research) has successfully...
Rolapitant reduces nausea and vomiting in phase III trial
9/29/2014
Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time at the ESMO 2014 Congress in...